Concepedia

Author

William Walsh

University of Massachusetts Chan Medical School

Also Known As

Edward Fitts, W V Walsh, W Walsh, W. V. Walsh, W. Walsh, W.V. Walsh, Walsh W, William K. Walsh, William V Walsh, William V. Walsh

72

Publications

7.2K

Citations

13

H-Index

47

Concepts

All Affiliations

University of Massachusetts Chan Medical SchoolJohns Hopkins UniversityUniversity of Wisconsin–MadisonPenn State Milton S. Hershey Medical CenterMerck & Co., Inc., Rahway, NJ, USA (United States)
WW

About

William Walsh is an author at University of Massachusetts Chan Medical School specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

6.9K

2

Cell Biology

2

2

4.9K

3

Health Sciences

1

1

13

4

Blood Transplantation

1

1

21

5

Gastroenterology

1

1

11

William Walsh

×

16

Publications

7.1K

Citations

12

H-Index

YearCitations

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

Michael B. Kastan, Qimin Zhan, Wafik S. El‐Deiry,

Cell

1992

3.1K

Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Steven J. Kuerbitz, Beverly Plunkett, William Walsh,

Proceedings of the National Academy of Sciences

1992

1.9K

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau,

The Lancet

2018

1.6K

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra,

The Lancet Oncology

2024

174

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Sameer A. Parikh, Hagop M. Kantarjian, Aaron D. Schimmer,

Clinical Lymphoma Myeloma & Leukemia

2010

85

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Bilal Piperdi, William Walsh, Kendra Bradley,

Journal of Thoracic Oncology

2012

32

Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience

Mohammed Salhab, Yazan Migdady, Melanie Donahue,

Journal for ImmunoTherapy of Cancer

2018

31

Population‐based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease

John M. Varlotto, Richard Voland, Kerrie McKie,

Cancer Medicine

2018

27

Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate Cancer

Mary-Ellen Taplin, Wanling Xie, Glenn J. Bubley,

Journal of Clinical Oncology

2006

25

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer

Tianhong Li, Bilal Piperdi, William Walsh,

Clinical Lung Cancer

2016

25

Page 1